Comparison of Post-Vaccination Cellular Immune Response in Patients with Common Variable Immune Deficiency.
CVID
adjuvanted influenza vaccines
azoximer bromide
influenza
toll-like receptors
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
17
06
2024
revised:
14
07
2024
accepted:
18
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
The problem of identifying vaccine-specific T-cell responses is still a matter of debate. Currently, there are no universal, clearly defined, agreed upon criteria for assessing the effectiveness of vaccinations and their immunogenicity for the cellular component of immunity, even for healthy people. But for patients with inborn errors of immunity (IEI), especially those with antibody deficiencies, evaluating cellular immunity holds significant importance. To examine the effect of one and two doses of inactivated adjuvanted subunit influenza vaccines on the expression of endosomal Toll-like receptors (TLRs) on the immune cells and the primary lymphocyte subpopulations in patients with common variable immunodeficiency (CVID). During 2018-2019, six CVID patients received one dose of a quadrivalent adjuvanted influenza vaccine; in 2019-2020, nine patients were vaccinated with two doses of a trivalent inactivated influenza vaccine. The proportion of key lymphocyte subpopulations and expression levels of TLRs were analyzed using flow cytometry with monoclonal antibodies. No statistically significant alterations in the absolute values of the main lymphocyte subpopulations were observed in CVID patients before or after vaccination with the different immunization protocols. However, after vaccination, a higher expression of TLR3 and TLR9 in granulocytes, monocytes, and lymphocytes was found in those patients who received two vaccine doses rather than one single dose. This study marks the first instance of using a simultaneous two-dose vaccination, which is associated with an elevated level of TLR expression in the immune cells. Administration of the adjuvanted vaccines in CVID patients appears promising. Further research into their impact on innate immunity and the development of more effective vaccination regimens is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
The problem of identifying vaccine-specific T-cell responses is still a matter of debate. Currently, there are no universal, clearly defined, agreed upon criteria for assessing the effectiveness of vaccinations and their immunogenicity for the cellular component of immunity, even for healthy people. But for patients with inborn errors of immunity (IEI), especially those with antibody deficiencies, evaluating cellular immunity holds significant importance.
AIM
OBJECTIVE
To examine the effect of one and two doses of inactivated adjuvanted subunit influenza vaccines on the expression of endosomal Toll-like receptors (TLRs) on the immune cells and the primary lymphocyte subpopulations in patients with common variable immunodeficiency (CVID).
MATERIALS AND METHODS
METHODS
During 2018-2019, six CVID patients received one dose of a quadrivalent adjuvanted influenza vaccine; in 2019-2020, nine patients were vaccinated with two doses of a trivalent inactivated influenza vaccine. The proportion of key lymphocyte subpopulations and expression levels of TLRs were analyzed using flow cytometry with monoclonal antibodies.
RESULTS
RESULTS
No statistically significant alterations in the absolute values of the main lymphocyte subpopulations were observed in CVID patients before or after vaccination with the different immunization protocols. However, after vaccination, a higher expression of TLR3 and TLR9 in granulocytes, monocytes, and lymphocytes was found in those patients who received two vaccine doses rather than one single dose.
CONCLUSION
CONCLUSIONS
This study marks the first instance of using a simultaneous two-dose vaccination, which is associated with an elevated level of TLR expression in the immune cells. Administration of the adjuvanted vaccines in CVID patients appears promising. Further research into their impact on innate immunity and the development of more effective vaccination regimens is warranted.
Identifiants
pubmed: 39203969
pii: vaccines12080843
doi: 10.3390/vaccines12080843
pmc: PMC11360582
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:39-46
pubmed: 26256294
Folia Med Cracov. 2020;60(3):5-16
pubmed: 33582741
Pediatr Infect Dis J. 2011 Jan;30(1):67-9
pubmed: 20724956
F1000Res. 2022 Mar 2;11:259
pubmed: 36176546
Ann N Y Acad Sci. 2010 Jan;1183:58-68
pubmed: 20146708
Physiol Genomics. 2007 Sep 19;31(1):114-25
pubmed: 17550995
J Allergy Clin Immunol. 2014 Apr;133(4):961-6
pubmed: 24582311
Zh Mikrobiol Epidemiol Immunobiol. 2016 Sep;(5):23-28
pubmed: 30695345
Oncoimmunology. 2012 Aug 1;1(5):581-592
pubmed: 22934250
Clin Transl Immunology. 2020 Oct 16;9(10):e1199
pubmed: 33088507
J Immunol. 2001 Aug 1;167(3):1379-86
pubmed: 11466356
Clin Exp Immunol. 2009 Jun;156(3):446-54
pubmed: 19438597
Nat Rev Immunol. 2007 Mar;7(3):179-90
pubmed: 17318230
Eur J Public Health. 2019 Oct 1;29(5):900-905
pubmed: 30929026
Cell Tissue Res. 2011 Jan;343(1):131-40
pubmed: 20824286
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
J Leukoc Biol. 2004 Mar;75(3):422-7
pubmed: 14726494
Clin Immunol. 2011 Nov;141(2):161-8
pubmed: 21889412
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651211
Hum Vaccin Immunother. 2012 Jan;8(1):81-8
pubmed: 22252006
J Investig Allergol Clin Immunol. 2018;28(3):172-181
pubmed: 29345621
Hum Vaccin Immunother. 2018;14(12):2971-2978
pubmed: 30183490
Blood. 2008 Jul 15;112(2):277-86
pubmed: 18319398
Front Immunol. 2019 Nov 28;10:2693
pubmed: 31849934
J Immunol. 2000 Jan 1;164(1):488-94
pubmed: 10605046
Semin Immunol. 2009 Aug;21(4):185-93
pubmed: 19502082
Clin Exp Immunol. 2000 Sep;121(3):506-14
pubmed: 10971518
Int Rev Immunol. 2016;35(1):7-24
pubmed: 26959802
J Immunol. 2007 Mar 15;178(6):3932-43
pubmed: 17339494
Blood. 2003 Aug 1;102(3):956-63
pubmed: 12689944
Trends Mol Med. 2005 Aug;11(8):370-6
pubmed: 15996517
Pediatr Allergy Immunol. 2017 Aug;28(5):478-484
pubmed: 28512785
Immunol Rev. 2006 Jun;211:303-9
pubmed: 16824137
BMC Infect Dis. 2014 Jul 03;14:365
pubmed: 24993051
J Immunol. 2007 Feb 15;178(4):2182-91
pubmed: 17277123
Clin Exp Immunol. 2012 Nov;170(2):202-11
pubmed: 23039891
Scand J Immunol. 2013 May;77(5):405-12
pubmed: 23432692
Eur J Immunol. 2006 Apr;36(4):810-6
pubmed: 16541472
Science. 2002 Dec 13;298(5601):2199-202
pubmed: 12481138
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
J Clin Immunol. 2021 Oct;41(7):1621-1632
pubmed: 34247288
J Stat Softw. 2016;75:
pubmed: 32655332
J Allergy Clin Immunol. 2009 Aug;124(2):349-56, 356.e1-3
pubmed: 19592080
J Immunol. 1996 Oct 1;157(7):2947-52
pubmed: 8816401
Behav Res Methods. 2017 Aug;49(4):1494-1502
pubmed: 27620283
J Investig Allergol Clin Immunol. 2016;26(3):209-11
pubmed: 27326997
J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1066-1075
pubmed: 27836056
J Virol. 2010 Sep;84(18):9217-26
pubmed: 20592069
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2332-2340.e5
pubmed: 32330665
Immunotherapy. 2017 Sep;9(12):1035-1050
pubmed: 28871852
Clin Immunol. 2006 Apr;119(1):51-8
pubmed: 16413828
Clin Immunol. 2010 Aug;136(2):228-35
pubmed: 20421178
Cell Immunol. 2017 May;315:11-17
pubmed: 28284485
Allergol Immunopathol (Madr). 2018 Mar - Apr;46(2):127-135
pubmed: 28735808
J Allergy Clin Immunol. 2020 Aug;146(2):417-428
pubmed: 32057767
J Allergy Clin Immunol. 2018 Feb;141(2):730-740
pubmed: 28554560
J Clin Immunol. 2021 Feb;41(2):362-373
pubmed: 33190167
Sci Rep. 2017 Jan 05;7:39710
pubmed: 28054583
Vaccines (Basel). 2018 Jul 31;6(3):
pubmed: 30065162
Clin Exp Immunol. 1995 Nov;102(2):286-9
pubmed: 7586680
J Investig Allergol Clin Immunol. 2016;26(4):233-43
pubmed: 27374799
Int Arch Allergy Immunol. 2016;171(3-4):180-193
pubmed: 28013299
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
J Immunol. 2006 Feb 1;176(3):1978-87
pubmed: 16424230
Vaccine. 2016 Jul 29;34(35):4092-4102
pubmed: 27381642
Nature. 2005 Feb 24;433(7028):887-92
pubmed: 15711573
Immunity. 2007 Aug;27(2):240-52
pubmed: 17723216
Clin Immunol. 2017 Feb;175:124-132
pubmed: 27664934
Blood. 2003 Jun 1;101(11):4500-4
pubmed: 12560217
Clin Exp Immunol. 2006 Sep;145(3):420-7
pubmed: 16907909
Immunotherapy. 2015;7(12):1273-92
pubmed: 26289364
J Allergy Clin Immunol. 2018 Feb;141(2):474-481
pubmed: 29288077
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89
pubmed: 21643519
Expert Rev Vaccines. 2013 Sep;12(9):1085-94
pubmed: 24024871
J Allergy Clin Immunol. 2019 Dec;144(6):1660-1673
pubmed: 31445098
Vaccine. 2016 May 5;34(21):2417-2423
pubmed: 27055021
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
Nature. 2005 Nov 17;438(7066):364-8
pubmed: 16292312
Scand J Immunol. 2011 Aug;74(2):210-8
pubmed: 21438900
Blood. 2002 Mar 15;99(6):2131-7
pubmed: 11877289
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
J Exp Med. 2014 Sep 22;211(10):2033-45
pubmed: 25225461
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:3-12
pubmed: 26256290
Clin Exp Immunol. 2006 May;144(2):233-8
pubmed: 16634796
J Allergy Clin Immunol. 2018 Dec;142(6):1922-1931.e2
pubmed: 29678747